Teon Therapeutics

Teon Therapeutics is a private, San Francisco-based biotech founded in 2019, operating at the intersection of cancer metabolism and immuno-oncology. The company is building a focused pipeline of first- and best-in-class oral GPCR-targeted therapies designed to reverse immune suppression in the tumor microenvironment. With a leadership team experienced in oncology drug development, Teon aims to expand the reach of immunotherapy beyond the current 12% of solid tumor patients who benefit, addressing a significant unmet need. The company is currently in the clinical stage, advancing its novel candidates.

Small molecule drug discovery platform targeting untapped metabolic signaling pathways and G-protein coupled receptors (GPCRs) to reverse immune suppression in the tumor microenvironment.

The field of next-generation immuno-oncology is highly competitive, with numerous companies exploring metabolic modulators, novel immune targets, and combination strategies. Teon must differentiate its specific GPCR biology and demonstrate superior clinical efficacy to compete with large pharma and well-funded biotechs.